Oxford Biomedica (LON:OXB) Price Target Lowered to GBX 900 at Royal Bank Of Canada

Oxford Biomedica (LON:OXB) had its price target cut by research analysts at Royal Bank Of Canada from GBX 1,140 to GBX 900 in a note issued to investors on Monday,London Stock Exchange reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price target would indicate a potential upside of 82.87% from the stock’s previous close.

Separately, Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 8.27 price target on shares of Oxford Biomedica in a research report on Tuesday, June 2nd. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of GBX 621.85.

Oxford Biomedica Stock Down 2.5%

OXB opened at GBX 492.15 on Monday. The firm has a 50 day moving average price of GBX 601.87 and a 200 day moving average price of GBX 647.85. The company has a market cap of £595.69 million, a PE ratio of -18.28 and a beta of 1.12. Oxford Biomedica has a 1 year low of GBX 423.50 and a 1 year high of GBX 952. The company has a debt-to-equity ratio of 162.16, a quick ratio of 1.67 and a current ratio of 2.20.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.